What Happened?
Cambridge, MA-based Enzyvant Appointed Johanna Rossell as Chief Commercial Officer
About the Company
Enzyvant is also advancing the development of RVT-802, an investigational tissue-based biologic therapy for the potential treatment of primary immune deficiency associated with complete DiGeorge Syndrome. RVT-802 has been granted orphan drug designation, Breakthrough Therapy designation, Regenerative Medicine Advanced Therapy designation, and pediatric rare disease designation by the U.S. Food and Drug Administration. Enzyvant anticipates a potential BLA filing for RVT-802 in the first half of 2018. Enzyvant plans to develop treatments for additional rare diseases with high unmet need.
About the Person
Johanna Rossell is Chief Commercial Officer at Enzyvant. Previously, Johanna held various senior HR leadership roles in the industry.
Info Source
News
Short Profile